Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Echo Therapeutics Inc. (NASDAQ: ECTE) shares soared 72.86 percent to close at $4.65 a share Tuesday. The stock traded between $3.63 and $4.91 on volume 11.01 million shares traded. The company has announced positive CE Mark regulatory trial results for the Symphony CGM System in surgical patients in hospital critical care units. Shares of Echo Therapeutics have fallen approximately 55.0 percent year-to-date.
Get more information on Echo Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/ECTE
Extreme Networks, Inc. (NASDAQ: EXTR) shares jumped 8.70 percent to close at $6.87 a share Tuesday. The stock traded between $6.48 and $6.92 on volume 3.23 million shares traded. Needham analysts have recently initiated coverage on the company with a "buy" rating. Shares of Extreme Networks have gained approximately 90.0 percent year-to-date.
Get more information on Extreme Networks free access to the in-depth equity report at:
www.FiveStarEquities.com/EXTR
Hormel Foods Corporation (NYSE: HRL) shares gained 5.91 percent to close at $44.95 a share Tuesday. The stock traded between $44.01 and $45.53 on volume of 2.28 million shares traded. The company reported record dollar sales of $2.3 billion for the fourth quarter of fiscal 2013, an increase of 7.0 percent when compared to a year ago. Shares of Hormel Foods have gained approximately 44.0 percent year-to-date.
Get more information on Hormel Foods and free access to the in-depth equity report at:
www.FiveStarEquities.com/HRL
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares spiked 7.75 percent to close at $17.79 a share Tuesday. The stock traded between $17.06 and $18.32 on volume of 4.14 million shares traded. WBB Securities’ analysts have recently upgraded the company’s rating from “sell” to “speculative” buy. Shares of Sarepta Therapeutics have fallen approximately 30.0 percent year-to-date.
Get more information on Sarepta Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/SRPT
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com